Lymphoma Specialized Program of Research Excellence (SPORE)

描述(申请人提供)：尽管淋巴系统恶性肿瘤有所进展，但大多数仍是无法治愈的，并导致患者死亡。爱荷华大学/梅奥诊所淋巴瘤孢子(UI/MC孢子)是一个非常成功的转化研究项目，它利用了艾奥瓦大学霍尔顿综合癌症中心和梅奥诊所综合癌症中心这两个NCI指定的综合性癌症中心的转化淋巴瘤项目的组合优势。在前一个供资期间，UI/MC取得了很高的成效。科学成就包括探索新型治疗剂免疫刺激CpG ODN作为B细胞恶性肿瘤潜在治疗方法的潜力的翻译研究，开发可能影响我们对淋巴瘤生物学的理解的新的成像方法，以及可能对淋巴瘤的治疗产生重大影响的生物标记物的研究。作为UI/MC孢子的一部分，已经开始了五项早期治疗临床试验，其中包括四项研究，这些研究都是在爱荷华州和梅奥进行的。自2002年启动UI/MC孢子以来，已有96名受试者参加了治疗试验，17名受试者参加了新的成像试验。爱荷华州和梅奥州的1331名受试者的DNA和广泛的临床数据已被收集，作为UI/MC淋巴瘤孢子分子流行病学资源的一部分，该资源将作为一种工具越来越有价值，用于识别有助于淋巴肿大和治疗反应的遗传因素。 这份续签申请旨在加快UI/MC孢子的进度，由四个研究项目、四个核心资源以及职业发展和发展研究计划组成。具体项目如下： 1)B细胞恶性肿瘤免疫治疗的新途径 2)淋巴瘤的信号转导抑制治疗 3)B细胞NHL中APRIL和BLYS的生物学和流行病学 4)B细胞非霍奇金淋巴瘤肿瘤微环境中的调节性T细胞核心资源包括管理、生物统计学和生物信息学、生物谱学和支持临床试验和UI/MC孢子的分子流行病学资源的临床研究。 医学会/医委会孢子部门的所有单位都在努力利用这两个机构的资源，以加快将发现转化为预防和治疗淋巴瘤的新的、更好的方法。

DESCRIPTION (provided by applicant): Despite progress in lymphoid malignancies, most are still incurable and lead to the death of the patient. The University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) is a highly successful translational research program that takes advantage of the combined strengths of the translational lymphoma programs of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Comprehensive Cancer Center - two NCI-designated comprehensive cancer centers. During the prior funding period, the UI/MC has been highly productive. Scientific accomplishments include translational studies exploring the potential of a novel therapeutic agent, immunostimulatory CpG ODN, as a potential treatment for B cell malignancies, development of novel approaches to imaging that could impact on our understanding of lymphoma biology, and investigation into biomarkers that could have a significant impact on management of lymphoma. Five early phase therapeutic clinical trials have been opened as part of the UI/MC SPORE, including four studies that have accrued subjects at both Iowa and Mayo. Since initiation of the UI/MC SPORE in 2002, 96 subjects have been enrolled on therapeutic trials and 17 on novel imaging trials. DNA and extensive clinical data have been collected on 1331 subjects at Iowa and Mayo as part of the UI/MC Lymphoma SPORE Molecular Epidemiologic Resource which will be increasingly valuable as a tool for identifying genetic factors that contribute to lymphomagenesis and response to therapy. This renewal application is designed to accelerate the progress of the UI/MC SPORE and consists of four research projects, four core resources, and the Career Development and Developmental Research Programs. Specific projects are as follows: 1) A novel approach to the immunotherapy of B cell malignancies 2) Signal transduction inhibitor therapy for lymphoma 3) Biology and Epidemiology of APRIL and BLyS in B-cell NHL 4) Regulatory T-cells in the tumor microenvironment of B-cell non-Hodgkin lymphoma Core resources include Administration, Biostatistics and Bioinformatics, Biospecimens, and Clinical Research that supports both clinical trials and the Molecular Epidemiology Resource of the UI/MC SPORE. All units within the UI/MC SPORE work to draw on the resources of both institutions to expedite the translation of discoveries into new and better approaches to the prevention and treatment of lymphoma.